Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1733)	12/21/2006 11:28:12 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

ENMD Didn't do much after the news this morning,but did a little better AHs.<g> bigcharts.marketwatch.com EntreMed's Panzem(R) Demonstrates Antitumor Activity in Brain Tumor Model Thursday December 21, 8:30 am ET Published Preclinical Results Show Substantial Tumor Shrinkage ROCKVILLE, Md., Dec. 21 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD - News), a clinical-stage pharmaceutical company developing therapeutics primarily for the treatment of cancer and inflammatory diseases, today announced the publication of preclinical results for its lead clinical- stage compound, Panzem® (2ME2 or 2-methoxyestradiol), in an orthotopic brain tumor model. The results of the studies, conducted by EntreMed collaborators at Emory University, were published in the December 2006 issue of Cancer Research (Vol. 66, Issue 24). Using non-invasive imaging and histological evaluation in a preclinical orthotopic glioma tumor model, 2ME2 treatment resulted in a dose-dependent reduction in tumor size. Tumor burden in the brain was reduced by 77% following 2ME2 treatment, as determined by magnetic resonance imaging. Further histological examination of the 2ME2 treated tumors demonstrated a dose-dependent decrease in acetylated tubulin, a marker of microtubule disruption. A decrease in acetylated tubulin is consistent with 2ME2 causing tumor inhibition through interfering with microtubules. In this preclinical study, 2ME2 also showed a significant improvement in tissue oxygenation, which should result in improved responsiveness to therapy, and a decrease in HIF-1alpha (hypoxia inducible factor-1alpha). HIF-1alpha is a nuclear transcription factor that governs gene expression of proteins involved in tumor cell survival pathways, including angiogenesis. 2ME2 is an orally-active small molecule that attacks tumor cells through multiple mechanisms of action and blocks the development of new blood vessels that feed tumor cells. Panzem® NCD, an oral liquid formulation, has been shown to result in enhanced drug levels of 2ME2 in patients and has been shown in preclinical studies to significantly increase the drug's bioavailability and activity. EntreMed is currently conducting Phase 1 and 2 clinical studies with Panzem® NCD in cancer patients, including a Phase 2 study in patients with glioblastoma multiforme (GBM) at the Brain Tumor Center at Duke University Medical Center. Previously, EntreMed has presented preclinical data showing that combination treatment with 2ME2 and Temodar® (temozolomide) resulted in a marked enhancement in tumor inhibition compared to either agent alone in a glioblastoma model. Collectively, these preclinical studies support the clinical evaluation of Panzem® in the GBM patient population. Carolyn F. Sidor, M.D., M.B.A, EntreMed Vice President and Chief Medical Officer, commented, "We are encouraged by the outcome of this preclinical GBM study, which has resulted from our long-standing collaboration with researchers at Emory University. These tumors are highly angiogenic and frequently harbor PTEN mutations, which result in high levels of HIF-1alpha protein, a pro-survival and pro-angiogenic transcription factor. We are currently evaluating Panzem® NCD as a single agent in patients with GBM, with plans to initiate a combination clinical study with Panzem® NCD and Temodar®, an approved anticancer therapy, in this patient population in 2007." Snip Bernard